ALT Jerome Benedict Durso bought Altimmune, Inc. shares — SEC Form 4BUYAltimmune, Inc.

ALT is down 25% over the last 30 days and 34% over the past year, trading 59.64% below its 52-week high of $7.73.

• •Q1 2026 earnings call on May 13, 2026, where management highlighted a cash balance of approximately $535 million and plans to begin a global Phase III trial of pemvidutide in the second half of 2026.
• •Truist initiated coverage on April 26, 2026, with a $12 price target implying 315% upside potential.
• •The start of a global Phase III trial of pemvidutide in the second half of 2026.

• •The stock carries a short interest of 18.26% of the float, which could fuel volatility if the clinical thesis fails to materialize.
• •The company reported a net loss and increased expenses in its Q1 2026 earnings call, raising questions about near-term profitability.